RU2014151424A - Термостабильные составы вакцины - Google Patents
Термостабильные составы вакцины Download PDFInfo
- Publication number
- RU2014151424A RU2014151424A RU2014151424A RU2014151424A RU2014151424A RU 2014151424 A RU2014151424 A RU 2014151424A RU 2014151424 A RU2014151424 A RU 2014151424A RU 2014151424 A RU2014151424 A RU 2014151424A RU 2014151424 A RU2014151424 A RU 2014151424A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- composition according
- sugar
- antigen
- surfactant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 154
- 229960005486 vaccine Drugs 0.000 title claims abstract 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 24
- 239000004094 surface-active agent Substances 0.000 claims abstract 21
- 229910052782 aluminium Inorganic materials 0.000 claims abstract 16
- 239000002671 adjuvant Substances 0.000 claims abstract 15
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract 15
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract 14
- 239000000427 antigen Substances 0.000 claims abstract 14
- 102000036639 antigens Human genes 0.000 claims abstract 14
- 108091007433 antigens Proteins 0.000 claims abstract 14
- 235000001014 amino acid Nutrition 0.000 claims abstract 13
- 150000001413 amino acids Chemical class 0.000 claims abstract 13
- 239000004475 Arginine Substances 0.000 claims abstract 12
- 239000004471 Glycine Substances 0.000 claims abstract 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract 12
- 235000004279 alanine Nutrition 0.000 claims abstract 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract 6
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract 6
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract 6
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract 4
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims abstract 4
- 101710194807 Protective antigen Proteins 0.000 claims 9
- 229960002235 anthrax antigen Drugs 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 241000193738 Bacillus anthracis Species 0.000 claims 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims 5
- 238000004108 freeze drying Methods 0.000 claims 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 5
- 229940068977 polysorbate 20 Drugs 0.000 claims 5
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 4
- 230000001717 pathogenic effect Effects 0.000 claims 4
- 238000003860 storage Methods 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- 239000000706 filtrate Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 238000005571 anion exchange chromatography Methods 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000000859 sublimation Methods 0.000 claims 2
- 230000008022 sublimation Effects 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229940037003 alum Drugs 0.000 claims 1
- -1 aluminum compound Chemical class 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664062P | 2012-06-25 | 2012-06-25 | |
| US61/664,062 | 2012-06-25 | ||
| US201361801385P | 2013-03-15 | 2013-03-15 | |
| US61/801,385 | 2013-03-15 | ||
| PCT/US2013/047712 WO2014004578A1 (en) | 2012-06-25 | 2013-06-25 | Temperature stable vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014151424A true RU2014151424A (ru) | 2016-08-20 |
Family
ID=49783811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014151424A RU2014151424A (ru) | 2012-06-25 | 2013-06-25 | Термостабильные составы вакцины |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150335752A1 (enExample) |
| EP (1) | EP2863898A4 (enExample) |
| JP (1) | JP2015525748A (enExample) |
| KR (1) | KR20150034170A (enExample) |
| CN (1) | CN104470506A (enExample) |
| AU (1) | AU2013280480B2 (enExample) |
| CA (1) | CA2877130A1 (enExample) |
| HK (1) | HK1207312A1 (enExample) |
| IL (1) | IL236380A0 (enExample) |
| IN (1) | IN2015MN00038A (enExample) |
| RU (1) | RU2014151424A (enExample) |
| SG (1) | SG11201408262XA (enExample) |
| WO (1) | WO2014004578A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015100344A1 (en) * | 2013-12-27 | 2015-07-02 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
| IL310015B1 (en) * | 2013-12-31 | 2025-10-01 | Access To Advanced Health Inst | Single vial formulation |
| EP3319930A4 (en) * | 2015-07-07 | 2019-04-10 | NanoBio Corporation | METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS |
| GB2556002B (en) | 2015-07-07 | 2020-12-16 | Bluewillow Biologics Inc | Methods and compositions for nanoemulsion vaccine formulations |
| US20170007690A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilization of anthrax recombinant protective antigen |
| WO2018050873A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| JP7170329B2 (ja) * | 2016-09-16 | 2022-11-14 | ロイコケア・アクチェンゲゼルシャフト | 処理中の生物医薬製品の安定化のための新規な方法 |
| WO2018050872A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| KR101744900B1 (ko) | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0762897T3 (da) * | 1994-06-02 | 2003-07-21 | Elan Drug Delivery Ltd | Fremgangsmåde til forebyggelse af aggregering af proteiner/peptider ved rehydratisering eller optøning |
| US7201912B2 (en) * | 2002-04-12 | 2007-04-10 | Emergent Biodefense Operation Lansing Inc. | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
| JO3324B1 (ar) * | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| CN100556400C (zh) * | 2006-07-20 | 2009-11-04 | 上海交通大学 | 载有活性疫苗或抗体的多糖玻璃体微粒的制备方法 |
| WO2008079464A2 (en) * | 2006-09-08 | 2008-07-03 | Becton, Dickinson And Company | Stable powder formulations of alum-adsorbed vaccines |
| AU2008231072B2 (en) * | 2007-03-22 | 2013-08-01 | The Regents Of The University Of Colorado | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| US8778359B2 (en) * | 2008-07-30 | 2014-07-15 | Emergent Biosolutions Inc. | Stable anthrax vaccine formulations |
| US20110212127A1 (en) * | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
| AU2009338516A1 (en) * | 2009-01-22 | 2011-08-18 | Pharmathene, Inc. | Stable vaccine compositions and methods of use |
-
2013
- 2013-06-25 HK HK15108032.6A patent/HK1207312A1/xx unknown
- 2013-06-25 KR KR20157000755A patent/KR20150034170A/ko not_active Withdrawn
- 2013-06-25 WO PCT/US2013/047712 patent/WO2014004578A1/en not_active Ceased
- 2013-06-25 AU AU2013280480A patent/AU2013280480B2/en not_active Ceased
- 2013-06-25 IN IN38MUN2015 patent/IN2015MN00038A/en unknown
- 2013-06-25 US US14/410,942 patent/US20150335752A1/en not_active Abandoned
- 2013-06-25 JP JP2015520412A patent/JP2015525748A/ja not_active Withdrawn
- 2013-06-25 SG SG11201408262XA patent/SG11201408262XA/en unknown
- 2013-06-25 EP EP13809706.8A patent/EP2863898A4/en not_active Withdrawn
- 2013-06-25 CA CA2877130A patent/CA2877130A1/en not_active Abandoned
- 2013-06-25 RU RU2014151424A patent/RU2014151424A/ru not_active Application Discontinuation
- 2013-06-25 CN CN201380037918.7A patent/CN104470506A/zh active Pending
-
2014
- 2014-12-21 IL IL236380A patent/IL236380A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013280480B2 (en) | 2018-03-15 |
| AU2013280480A1 (en) | 2015-01-22 |
| JP2015525748A (ja) | 2015-09-07 |
| CN104470506A (zh) | 2015-03-25 |
| EP2863898A4 (en) | 2016-04-27 |
| IL236380A0 (en) | 2015-02-26 |
| US20150335752A1 (en) | 2015-11-26 |
| IN2015MN00038A (enExample) | 2015-10-16 |
| HK1207312A1 (en) | 2016-01-29 |
| WO2014004578A1 (en) | 2014-01-03 |
| KR20150034170A (ko) | 2015-04-02 |
| CA2877130A1 (en) | 2014-01-03 |
| SG11201408262XA (en) | 2015-01-29 |
| EP2863898A1 (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014151424A (ru) | Термостабильные составы вакцины | |
| Dumpa et al. | Stability of vaccines | |
| US8795686B2 (en) | Stable, dried rotavirus vaccine, compositions and process for preparation thereof | |
| JP4902103B2 (ja) | 凍結乾燥フォームによる生物活性材料の保存 | |
| Glenn et al. | Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine | |
| DK2709657T3 (en) | Thermostable vaccine compositions and methods for their preparation | |
| US8216588B2 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| JP5307801B2 (ja) | 凍結乾燥フォームによる生物活性材料の防腐 | |
| ES2224646T3 (es) | Preparacion de un herpevirus estabilizado. | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| Hassett et al. | Development of a highly thermostable, adjuvanted human papillomavirus vaccine | |
| JP2019163271A (ja) | 熱安定性ワクチン製剤及びマイクロニードル | |
| JP5960120B2 (ja) | ウイルス粒子の安定化 | |
| US12186384B2 (en) | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens | |
| RU2014117068A (ru) | Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса | |
| FI3725330T3 (fi) | Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset | |
| AU2016210743A1 (en) | Inactivated dengue virus vaccine | |
| CN102802664B (zh) | 免疫原性组合物 | |
| CA2272245A1 (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| RU2013154779A (ru) | Композиции для иммунизации против staphylococcus aureus | |
| RU2012125254A (ru) | Составы антитела | |
| CN104271119A (zh) | 用于稳定干燥的生物材料的方法和组合物 | |
| CN103041383A (zh) | 一种活疫苗的耐热冻干保护剂、活疫苗冻干粉及其制备方法 | |
| IL316312A (en) | Dengue virus vaccine compound formulations | |
| JP2013531679A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180403 |